The company is raising its outlook for full year 2025 global net ORLADEYO revenue to between $590 million and $600 million and lowering its outlook for 2025 non-GAAP operating expenses, excluding stock-based compensation expense and transaction-related costs, to between $430 million and $440 million. These figures exclude revenue and expenses associated with the European ORLADEYO business in the fourth quarter of 2025 as the sale of this business has been completed. The company remains on track to deliver net income and positive cash flows for full year 2025. Positive cash flow refers to the improvement in cash, cash equivalents, restricted cash and investments from year end 2024 to year end 2025, not including the impact of debt prepayments or the sale of the European ORLADEYO business.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst reports Q3 adjusted EPS 16c, consensus 8c
- BioCryst Pharmaceuticals (BCRX) Q3 Earnings Cheat Sheet
- BioCryst’s Strategic Acquisition of Astria Therapeutics and Promising HAE Treatment Drive Buy Rating
- BioCryst price target raised to $26 from $24 at Cantor Fitzgerald
- BioCryst’s Strategic Acquisition of Astria Therapeutics: Enhancing HAE Portfolio with Navenibart